|

Cemiplimab-Rwlc Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since May 2026

Also known as: Libtayo

Pipeline

Phase 1: 1Phase 2: 1

Top Sponsors

  • H. Lee Moffitt Cancer Center and Research Institute1
  • Georgetown University1

Indications

  • Cancer2
  • Non-small Cell Lung Cancer Stage III1
  • Cutaneous Squamous Cell Carcinoma1
  • Merkel Cell Carcinoma1
  • Lung Cancer1

Washington D.C., District of Columbia1 trial

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Involvement

Lombardi Comprehensive Cancer Center, Georgetown University

Phase 2

Tampa, Florida1 trial

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Moffitt Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.